RenovoRx, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Revenue | $909.0K | $563.0K | $238.0K | $266.0K | $422.0K | $197.0K |
| Cost of Revenue | $143.0K | $84.0K | $28.0K | $53.0K | $152.0K | $94.0K |
| Gross Profit | $766.0K | $479.0K | $210.0K | $213.0K | $270.0K | $103.0K |
| Gross Margin | 84.3% | 85.1% | 88.2% | 80.1% | 64.0% | 52.3% |
| Operating Expenses | ||||||
| Research & Development | $1.2M | $1.2M | $1.5M | $1.7M | $1.4M | $1.6M |
| SG&A Expense | $2.9M | $2.7M | $2.2M | $1.7M | $1.5M | $1.6M |
| Operating Income | $-3.3M | $-3.5M | $-3.5M | $-3.2M | $-2.7M | $-3.1M |
| Operating Margin | -368.4% | -616.2% | -1,479.8% | -1,203.0% | -634.6% | -1,578.7% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | $0 |
| Net Income | $-2.9M | $-3.5M | $-2.9M | $-2.9M | $-2.9M | $-2.4M |
| Net Margin | -320.2% | -625.4% | -1,235.7% | -1,094.7% | -686.0% | -1,228.4% |
| EPS (Basic) | $-0.06 | $-0.09 | $-0.08 | $-0.08 | $-0.08 | $-0.08 |
| EPS (Diluted) | $-0.06 | $-0.09 | $-0.08 | $-0.08 | $-0.08 | $-0.08 |
| Shares Outstanding (Basic) | 47.3M | 38.0M | 35.3M | 36.6M | 36.6M | 31.4M |
| Shares Outstanding (Diluted) | 47.3M | 38.0M | 35.3M | 36.6M | 36.6M | 31.4M |
| Dividends Per Share | — | — | — | — | — | — |